HIGHLIGHTS
- What: Summary This study compared liquid and tablet forms of alendronate for osteoporosis treatment. The primary reasons for this discontinuation are drug-induced adverse effects and strict administration guidelines: the patient has to fast, swallow a large volume of plain water, and remain upright for 30 min . The authors aimed to evaluate the efficacy and safety of this newly developed drinkable alendronate in postmenopausal women with osteoporosis. The study showed exceptionally good compliance for both forms of alendronate and thus did not show any significant difference, probably because of its prospective nature.
- Who: Seungjin Baek . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.